Boca Raton, Florida — August 11, 2025 — Leads & Copy — Entero Therapeutics, Inc. (NASDAQ: ENTO) announced it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The transaction, priced at the market under Nasdaq rules, involves the sale of 4,878,841 pre-funded warrants and 9,757,682 common warrants to purchase one share of common stock per warrant, with a combined purchase price of $0.6149 for one pre-funded warrant and two common warrants. The company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.
The pre-funded warrants are immediately exercisable at $0.00001, while the common warrants are exercisable at $0.3649 per share and expire 60 months after the resale registration statement’s effective date.
The transaction is expected to close around August 11, 2025. Sichenzia Ross Ference Carmel LLP is legal counsel to the Company, and Kaufman & Canoles, P.C. is legal counsel to the investors.
Investor contact information:
Entero Investor Relations
investors@enterothera.com
Source: Entero Therapeutics, Inc.
